Zika in the Americas, year 2: What have we learned? What gaps remain? A report from the Global Virus Network


PII: S0166-3542(17)30400-X
DOI: 10.1016/j.antiviral.2017.06.001
Reference: AVR 4079

To appear in: Antiviral Research

Received Date: 26 May 2017
Accepted Date: 1 June 2017


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Zika in the Americas, Year 2: What have we learned? What gaps remain? A report from the Global Virus Network

Matthew T. Aliota\textsuperscript{a}, Leda Bassit*\textsuperscript{b}, Shelton S. Bradrick*\textsuperscript{c}, Bryan Cox*\textsuperscript{b}, Mariano A. Garcia-Blanco*\textsuperscript{c}, Christina Gavegnano*\textsuperscript{b}, Thomas C. Friedrich*\textsuperscript{d}, Thaddeus G. Golos\textsuperscript{d}\textsuperscript{e}\textsuperscript{f}, Diane E. Griffin,*\textsuperscript{g} Andrew Haddow,*\textsuperscript{h} Esper G. Kallas*\textsuperscript{a}, Uriel Kitron*\textsuperscript{i}, Marc Lecuit*\textsuperscript{k}\textsuperscript{l}, Diogo M. Magnani*\textsuperscript{m}, Caroline Marrs,*\textsuperscript{n} Natalia Mercer*, Edward McSweegan*, Lisa Ng*\textsuperscript{o}, David H. O’Connor*\textsuperscript{b}, Jorge E. Osorio*\textsuperscript{a}, Guilherme S. Ribeiro*\textsuperscript{o}, Michael Ricciardi*\textsuperscript{m}, Shannan L. Rossi,*\textsuperscript{f} George Saade,*\textsuperscript{n} Raymond F. Schinazi*\textsuperscript{b}, Geraldine O. Schott-Lerner*\textsuperscript{b}, Chao Shan*\textsuperscript{c}, Pei-Yong Shi*\textsuperscript{c}, David I. Watkins*\textsuperscript{m}, Nikos Vasilakis*\textsuperscript{s}, Scott C. Weaver*\textsuperscript{r}\textsuperscript{t}

* Global Virus Network, 725 West Lombard St., Baltimore, MD USA

\textsuperscript{a}Department of Pathobiological Sciences, University of Wisconsin-Madison
\textsuperscript{b}Center for AIDS Research, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
\textsuperscript{c}Department of Biochemistry and Molecular Biology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA
\textsuperscript{d}Wisconsin National Primate Research Center, University of Wisconsin-Madison.
\textsuperscript{e}Department of Comparative Biosciences, University of Wisconsin-Madison.
\textsuperscript{f}Department of Obstetrics and Gynecology, University of Wisconsin-Madison.
\textsuperscript{g}W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205
\textsuperscript{h}Virology Division, United States Army Medical Research Institute of Infectious Diseases. Ft. Detrick, MD 21702
\textsuperscript{i}Division of Clinical Immunology and Allergy, School of Medicine, University of São Paulo
\textsuperscript{j}Department of Environmental Sciences, Emory University, Atlanta, Georgia, USA
\textsuperscript{k}Institut Pasteur, Biology of Infection Unit and INSERM Unit 1117
\textsuperscript{l}Paris Descartes University, Sorbonne Paris Cité, and Division of Infectious Diseases and Tropical Medicine, Necker– Enfants Malades University Hospital, Institut Imagine, Paris, France
\textsuperscript{m}Department of Pathology, University of Miami, Miami, FL, USA.
\textsuperscript{n}Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA
\textsuperscript{o}Singapore Immunology Network, Agency for Science, Technology and Research (A*STAR), Singapore, Singapore
\textsuperscript{p}Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison
\textsuperscript{q}Instituto Gonçalo Moniz, Fundação Oswaldo Cruz and Instituto de Saúde Coletiva, Universidade Federal da Bahia, Salvador, Bahia, Brazil
\textsuperscript{r}Department of Microbiology & Immunology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA
\textsuperscript{s}Department of Pathology, Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA

1
*Corresponding author: Scott C. Weaver, Department of Microbiology and Immunology, 6200D Galveston National Laboratory, Galveston, Texas 77555-0610 USA: sweaver@utmb.edu
Abstract

In response to the outbreak of Zika virus (ZIKV) infection in the Western Hemisphere and the recognition of a causal association with fetal malformations, the Global Virus Network (GVN) assembled an international taskforce of virologists to promote basic research, recommend public health measures and encourage the rapid development of vaccines, antiviral therapies and new diagnostic tests. In this article, taskforce members and other experts review what has been learned about ZIKV disease in humans, its modes of transmission and the cause and nature of associated congenital manifestations. After describing the make-up of the taskforce, we summarize the emergence of Zika in the Americas, Africa and Asia, its spread by mosquitoes, and current control measures. We then review the spectrum of primary Zika virus disease in adults and children, sites of persistent infection and sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome, including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. After reviewing current understanding of the mechanisms of emergence of Zika virus, we consider the likely future of the pandemic.

Keywords

Zika virus, arbovirus, congenital manifestations, maternal-fetal transmission, antiviral therapy, vaccines
I. Introduction

Following on the heels of the Ebola epidemic in West Africa, the Zika virus (ZIKV) outbreak in the Western Hemisphere has led to the rapid mobilization of scientific resources to study the disease and initiate the development of specific countermeasures. As part of this response, the Global Virus Network (GVN) formed a task force of investigators from its worldwide Centers of Excellence to develop a coordinated program of research and to serve as a resource for scientists, physicians and public health officials dealing with the outbreak.

In this article, members of the GVN Zika task force and other experts review what has been learned about the disease in humans since an association with severe congenital manifestations was identified in 2015 [1]. The first section describes the make-up of the task force and its research program. The following sections review the emergence of the virus in the Americas, Africa and Asia, its transmission by mosquitoes and current control measures. We then review the spectrum of primary Zika virus disease in adults and children, sites of persistent infection and modes of sexual transmission, then examine what has been learned about maternal-fetal transmission and the congenital Zika syndrome (CZS), including knowledge obtained from studies in laboratory animals. Subsequent sections focus on vaccine development, antiviral therapeutics and new diagnostic tests. The concluding section of the paper reviews what has been learned about the mechanisms of emergence of Zika virus and considers the probable future course of the epidemic.

II. The Global Virus Network Zika Taskforce (Natalia Mercer, Edward McSweegan)

The mission of the GVN is to strengthen medical research and the public health response to emerging viruses and persisting viral threats [2]. Since its inception, the network has sought to carry out its mission through collaborative research projects, international meetings and training courses, professional publications and commentaries, and the engagement of expert medical virologists to advise on outbreak responses and research priorities. The GVN currently consists of 38 Centers and 6 Affiliates in 24 countries, focusing on all aspects of medical virology. For further information, readers are referred to the report of the most recent annual meeting and the website at [http://gvn.org](http://gvn.org).

In early 2016, the GVN joined with 30 other global health organizations to pledge support for the rapid and open sharing of research data on ZIKV. That pledge arose from an earlier World Health Organization consensus statement, in which international journal editors acknowledged that “timely and transparent pre-publication sharing of data and results during public health emergencies must become the global norm” (WHO, 2015) The GVN’s Zika task force was organized in February 2016 and widely announced at a meeting of American, European and Brazilian virologists (“Bridging the Sciences: Zika Virus,” Atlanta, Georgia, May 1–3, 2016). The expert members of the Zika taskforce are listed in Table 1.

In a survey of research needs, Center directors and task force members identified a lack of serum samples from definitively diagnosed patients as a major impediment to developing sensitive and specific diagnostic assays. Subsequently, the GVN obtained funds from the Allergan Foundation to support the establishment of a repository of high quality immune sera collected from a variety of convalescent patients with a definitive ZIKV diagnosis ([http://gvn.org/donation-allergan-foundation](http://gvn.org/donation-allergan-foundation)). In addition to aiding diagnostics development, these samples will be useful for the evaluation and comparison of immune responses to natural infection and future candidate vaccines.

Consultation among task force members has also led to a number of proposed research initiatives intended to help answer some of the many public health questions presented by the emergence and pandemic spread of ZIKV. They include:

- identifying opportunities to expand epidemiological studies;
• developing rapid diagnostics able to distinguish among regional arboviruses;
• developing and testing vaccines in susceptible populations;
• screening for existing and novel drugs to improve therapeutic options;
• performing basic research to identify mechanisms of viral infectivity, persistence, and the pathogenesis of congenital defects and neurological complications.

These initiatives are discussed in the following sections.

III. Emergence and spread of ZIKV infection

A. The Americas (Esper Kallas)

After occurring for decades throughout Africa and Asia, ZIKV became a major topic of intense discussion after a ravaging epidemic of infection was identified in Brazil. This resulted in several cases of GBS [3, 4] and an unexpected epidemic of newborns with microcephaly and other neurological defects [5-8]. More than one year later [9], intensive investigation revealed that a Polynesian ZIKV strain was probably introduced into Northeast Brazil coinciding with the 2013 Confederations Cup, a preparatory tournament for the football World Cup in Brazil. Everything seems to have started around the Tahiti vs. Spain match, in Recife, Pernambuco State capital [10].

ZIKV spread to neighboring States and regions [11], reaching most of the Brazilian Northeast, the North, the Midwest, and parts of the Southeast [12]. It did not take long to reach other countries in South [13, 14] and Central America [15], accompanied by an epidemic of GBS cases [16] and microcephaly [17]. Patients infected with ZIKV began to be identified in the U.S., initially imported from South and Central American countries [18, 19]. Autochthonous cases of Zika were later detected in 2016 in the continental United States in Florida [20] and later Texas [https://emergency.cdc.gov/han/han00399.asp]. As the virus continues to spread, it is still unclear how many cases of GBS, CZS, and other complications of ZIKV infection will be seen.

Several underlying conditions were in place to facilitate such a fast spread of ZIKV in the Americas. The first is the extensive presence of an efficient vector, *Ae. aegypti*, in vast swaths of the Americas, from Argentina to the U.S., with widely variable and sometimes quite inefficient mosquito control programs [21]. Second, the absence of previous ZIKV epidemics in the Americas, resulting in a massive susceptible population. The third is the virus’s ability to induce viremia shortly after the infectious mosquito bite [22], rendering each infected person an efficient reservoir for several days. Fourth, the mobility of people among states and countries in very short periods of time enhanced rapid spread among areas where the vector is present, with the potential of seeding new foci of transmission [19, 21].

Sexual transmission of ZIKV, reported since 2011 [23], is believed to have contributed to virus spread in Americas. As the virus can be detected in different body fluids [24], including semen from vasectomized men [25], sexual transmission may be responsible for an unknown proportion of cases within epidemic and endemic areas, as well as cases in non-endemic regions who acquired the virus from their sexual partners returning from areas of ZIKV transmission [26]. The contribution to the epidemic in regions with active mosquito-borne transmission is difficult to estimate because mosquito transmission of *Ae. aegypti*-borne viruses such as DENV often occurs nearly simultaneously within a household.

What is next? Areas with a large naïve population and abundant *Ae. aegypti* are expected to experience epidemic patterns of ZIKV transmission. However, as we accumulate areas with mounting herd immunity, ZIKV tends to spread in smaller outbreaks in the remaining susceptible groups. Although the susceptible populations in the Americas may be diminishing as future amplifiers of ZIKV, it is anticipated that further transmission may still occur.

B. Africa (Andrew Haddow)
Since 2015, the vast majority of ZIKV research has focused on those strains circulating outside of Africa; however, research in Africa has remained neglected and virus characterization and pathogenesis studies involving African strains have unfortunately been discounted by many – albeit inappropriately – as irrelevant. There is much to be gained through a thorough understanding of the ecology, epidemiology and pathogenesis of those ancestral ZIKV strains circulating in Africa. Such data will further our understanding of those ZIKV strains responsible for the large outbreaks reported throughout the tropics, which are known to cause severe clinical manifestations following infection in a subset of patients.

To date, the only continent where both members of the Spondweni flavivirus serogroup, ZIKV and Spondweni virus (SPONV), are known to circulate is Africa [27, 28]. While ZIKV strains constitute two phylogenetic lineages, the ancestral African lineage and the Asian lineage, these lineages represent a single virus serotype [28-33]. Symptomatic cases of ZIKV and SPONV infection both present as acute febrile illnesses, making clinical diagnosis in Africa challenging [27]. Additionally, serologic cross-reactivity has resulted in the misidentification of virus isolates and has traditionally confounded serosurveys where non-specific diagnostic assays were utilized [27, 34-36].

Sustained arbovirus surveillance efforts led to the original isolation of ZIKV from a sentinel rhesus macaque exposed in the Zika Forest, Uganda in 1947 (strain MR 766); a second isolate was made from a pool of *Aedes africanus* mosquitoes collected the following year (strain E1/48) [37]. The first human infection was reported in Uganda in 1962, probably resulting from a mosquito bite in the Zika Forest [35]. Due to the historic misidentification of the Chuku strain of SPONV as a ZIKV strain [34-36, 38], some early case reports of ZIKV infection actually represented SPONV infection. Furthermore, early experimental vector competence and virus characterization studies utilized SPONV rather than ZIKV [27, 38-40]. Due to their close relationship, further studies of cross-protection in mammalian hosts, as well as the potential for superinfection exclusion in competent mosquito vectors, are needed.

Our present knowledge regarding the geographic distribution of ZIKV in Africa primarily comes from surveillance efforts of a few laboratories East and West Africa in the second half of the 20th Century [30]. These studies indicate that ZIKV circulates in various niches throughout sub-Saharan Africa, and long-term enzootic circulation was recently demonstrated by serosurveys in several countries with previously reported ZIKV circulation (Gambia, Nigeria, Senegal and Tanzania)[41, 42]. However, the majority of surveillance has focused only on specific locales, resulting in an underestimation of the geographic distribution of ZIKV, as well as amplification hosts and mosquito vectors. Furthermore, shifts in the predominant vector species may have occurred during recent years, masking potential enzootic transmission cycles.

Field studies in East and West Africa, as well as experimental infections, indicate that ZIKV is primarily maintained in enzootic cycles involving sylvatic mosquitoes and NHPs [28, 34, 37]. Although evidence of present or prior ZIKV infection has been reported in several African NHP species, including the genera *Cercocebus, Cercopithecus, Chlorocebus, Colobus* and *Erythrocebus* [30, 41, 43], the primary NHP species involved in the ZIKV enzootic transmission cycle remain unknown. Serological evidence of past infection has also been reported in water buffalo, elephants, goats, hippos, impala, kongoni, lions, sheep, wildebeest and zebra [30, 44]. Yet, without viremia data, their role as amplification/reservoir hosts remains unresolved. While the ability of African rodents and birds serve as ZIKV amplification hosts remains unclear, their role may be limited based on previous field and experimental work involving SPONV [28].

Commonly incriminated mosquito vectors include: *Ae. africanus, Ae. furcifer, Ae. opok, Ae. vittatus* and *Ae. luteocephalus*; while potential amplification hosts likely involve multiple NHP species. Transovarial transmission in mosquitoes [45] and sexual transmission among NHPs (A. J. Haddow, unpublished) represent secondary ZIKV maintenance mechanisms. While *Aedes* spp. mosquitoes likely serve as the primary sylvatic mosquito vectors, future research should investigate the competence of additional mosquito genera, such as *Mansonia* spp., from which
both ZIKV and SPONV have been isolated [28]. Studies investigating variation in vector competence among geographically distinct mosquito populations are also needed.

Human infections with either African or Asian lineage ZIKV strains result in similar clinical presentations [46, 47]. Severe manifestations, such as GBS and CZS, have only been reported following infection with Asian lineage strains [43, 47, 48], although recent cases of CZS in Guinea-Bissau await confirmation of maternal ZIKV infection [49]. The lack of detected congenital defects in Africa is not well understood; it may be due to phenotypic variation between African and Asian strains, underreporting, misdiagnosis and/or immune protection resulting from ZIKV or related African flavivirus infection prior to puberty [27]. Although there have been multiple reports of sexual ZIKV transmission involving Asian lineage strains [50], the first sexually transmitted case was reported in the female sexual partner of a ZIKV-infected male who infected in Senegal [23]. Clinical and epidemiological studies are needed to determine if severe manifestations result from ZIKV infection with African lineage strains, as well as the role of sexual transmission in virus maintenance, transmission and spread.

In 2015, an Asian lineage ZIKV strain(s) caused an outbreak of human disease in the Cape Verde Islands, and this strain may have been introduced from the Americas, potentially leading to competition with African phenotypes. However, recent in vivo and in vitro experimental work using a limited number of ZIKV strains demonstrated that the African lineage exhibits increased fitness/virulence in vertebrates as well as mosquito vectors compared to Asian lineage strains [51-55]. Characterization of additional African strains in mosquito vectors, reservoir hosts and models for human infection, including early African isolates not available in reference collections are needed to fully explore the evolution of ZIKV, as well as to identify mutations potentially associated with differing phenotypes.

The lack of reported ZIKV epidemics in Africa must be taken with a grain of salt, as the majority of infections are asymptomatic and ZIKV co-circulates with a multitude of other pathogens that cause acute febrile illness, making diagnosis challenging. Seventy years after its discovery, the detection of ZIKV infections in Africa remains hindered by a lack of affordable and specific diagnostic assays, as well as support for longitudinal surveillance needed to better understand epidemiology, ecology and mechanisms of ZIKV maintenance and emergence. Improved understanding of the evolution of ZIKV and its pathogenicity as well as the emergence of epidemic cycles will depend on improved surveillance and epidemiologic studies in its ancestral Africa.

C. Asia (Lisa Ng)

The 2015-2016 ZIKV epidemic in Latin America that led to cases of devastating neuropathology and congenital neurological manifestation prompted a surge in awareness and monitoring of the virus in Asia [56]. However, it is known that ZIKV has been present in Asia for decades, and many countries have reported occasional or sporadic outbreaks of ZIKV infection [43]. In Southeast Asia, ZIKV was first isolated in Malaysian mosquitoes in the 1950s, and human infections were reported from Indonesia as early as in 1977 [57]. Reports of local transmission in Cambodia [46], the Philippines [58], Malaysia and Thailand have also been documented [59, 60]. Furthermore, indirect serological data of ZIKV infection using non-acute blood samples from Thailand, Malaysia, Indonesia and Vietnam suggest that ZIKV is endemic and widespread in this region [30]. However, natural ZIKV reservoirs, such as potentially NHPs, remain elusive and to date, no other arthropod species has been reported to harbor ZIKV other than *Aedes* spp. mosquitoes. Further surveillance will be crucial to understanding the pathogenicity of Asian ZIKV strains as well as their maintenance, transmission and spread in these countries.

More recently, Singapore reported its first case of local ZIKV transmission on 27 August, 2016 and phylogenetic analysis revealed that the virus strains form an earlier branch distinct from the 2015 outbreaks in Latin America [61]. This observation suggests that there are still
multiple strains of ZIKV in circulation with wide antigenic diversity and immunity. The presence of different ZIKV strains poses great challenges not only in the development of specific detection reagents, but also in the development of vaccines and therapeutics such as monoclonal antibodies.

Finally, phylogenetic studies indicate that Southeast Asia is the likely source of introduced ZIKV epidemics in Yap Island, 2007 [30] and independently into French Polynesia beginning in 2013, followed by spread to the Americas [10, 43]. However, due to the limited sampling in Asia, the exact source location in Southeast Asia remains unknown. Additional surveillance to identify genetic diversity in the Asian lineage may ultimately pinpoint the source of the Oceania/American outbreaks as well as any phenotypic variation critical to spread and pathogenicity seen in these recent outbreaks.

IV. Mosquito transmission and control measures (Nikos Vasilakis)

ZIKV transmission has been documented in two ecologically and evolutionarily distinct cycles: an ancestral, enzootic, sylvatic cycle, where the virus circulates between arboreal Aedes spp. mosquitoes and NHPs; and a human or urban cycle, between humans and peridomestic/domestic Aedes spp. mosquitoes (Fig. 1). Enzootic transmission has been documented in Africa [37] and there is indirect evidence that ZIKV may be circulating in the forests of Southeast Asia [62]. The major vectors in the African sylvatic cycle are Ae. africanus, Ae. luteocephalus, Ae. taylori and Ae. furcifer [34, 37, 45, 63-65], as well as several other arboreal Aedes species [45, 63, 66]. Non-Aedine mosquitoes such as, Anopheles coustani and Mansonia uniformis, which inhabit various rural habitats, have also been implicated in enzootic transmission. The isolation of ZIKV from Ae. vittatus sampled in an agricultural village within the ‘zone of emergence’ supports its putative role as a bridge vector into the human transmission cycle [45] (Fig. 1). ZIKV transmission in the urban cycle mainly involves the anthropophilic Ae. aegypti mosquito, [31, 52, 54, 67-74] and to lesser degree the peri-domestic Aedes albopictus [55, 75, 76], Ae. hensilli [77] and Ae. polynesiensis [73, 78] as vectors in niche ecotypes. Ae. albopictus is a highly invasive species, which has significantly expanded its global distribution in tropical as well as temperate settings, thus positioning it to become a significant ZIKV vector if conditions permit. However, its behavior is not as conducive to interhuman transmission as that of Ae. aegypti. So, taking into consideration its similar vector competence [55], Ae. albopictus is expected to play a secondary role in regions inhabited by similar populations.

To explain its spectacular global spread, it was suggested that ZIKV underwent adaptive evolution for more efficient urban transmission by Ae. aegypti mosquitoes, or for higher viremia in humans, which could enhance fetal infection. To date, most experimental studies [52, 54, 55] have failed to support these hypotheses, and cases of microcephaly possibly associated with maternal ZIKV infection in Thailand, Vietnam and Guinea Bissau [49] suggest that Asian and African ZIKV strains may be capable of producing CZS. However, a recent study reported that NS1 antigen levels affect ZIKV oral infectivity of Ae. aegypti [79]. In this study, virus strains from the Americas were more infectious than the FSS13025 2010 Cambodian strain, and an NS1-A188V substitution that evolved prior to spread into the Western Hemisphere enhanced both NS1 production and infection of this urban vector. Because other studies involving ZIKV strains that differ in this NS1 residue have not reported this infectivity difference, additional experiments with low-generation mosquito populations from other locations are needed to determine if this NS1 substitution may explain the explosive transmission and spread in the America.

The intensity of ZIKV transmission in the Americas is undoubtedly influenced by other factors, certainly including the stochastic introduction into regions with hundreds-of-millions of immunologically naïve humans. In mid-2016 an unsubstantiated report in the popular press from Brazil suggested that Cx. quinquefasciatus mosquitoes may be competent vectors of ZIKV transmission, followed by peer-reviewed report from China [80]. However, several experimental studies [81-85] demonstrated that American populations of this species as well as of the closely
related *Culex pipiens* are refractory to ZIKV infection and incapable of transmission. A possible explanation for these contradictory findings is that factors such as the mosquito virome and/or microbiome, or genetic differences in geographic mosquito populations, affects vector competence. Laboratory vector competence is only meaningful if a mosquito species repeatedly feeds on humans, and widely divergent results have been obtained by studies of *Cx. quinquefasciatus* feeding patterns [86-89].

The absence of licensed vaccines and therapeutics offer limited options, at least in the short term, to control the explosive global spread of ZIKV. The only currently viable and effective methods include reduction of contact between the vector and susceptible humans; and the elimination and/or reduction of vector populations. *Ae. aegypti* populations can theoretically be reduced using cost-effective approaches such as: community engagement and personal responsibility for eliminating or treating larval habitats; application of adulticide aerosols within homes or other places where people are exposed to biting vectors; release of genetically modified mosquitoes that express a dominant lethal gene resulting in the death of all offspring from matings with wild females, thus eliminating the risk for persistence of the transgene in nature; release of *Ae. aegypti* harboring endosymbiotic *Wolbachia* bacteria, which interfere with ZIKV replication and transmission; and the use of use of inexpensive and relatively maintenance-free lethal traps (reviewed in [1, 90-93]). All these novel approaches will face with logistical, technical and financial challenges to be implemented and in some cases sustained on a scale to protect large urban populations at risk.

Lastly a major determinant of ZIKV stability in the Americas will be its ability to establish an enzootic, NHP-hosted transmission cycle in the Americas. A recent modeling study [94] demonstrated a high probability of enzootic establishment across a wide range of biologically plausible parameters, such as host and vector population sizes, host birthrates, and the ZIKV force of infection. Several arboreal New World mosquitoes involved in the enzootic transmission of YFV, including *Haemagogus albomaculatus*, *H. spegazzini*, *H. janthinomys*, *Sabethes chloropterus*, *Sa. albipivus*, *Sa. glaucodaemon*, *Sa. soperi*, and *Sa. cyaneus*, *Psorophora ferox* and *Ae. serratus* (reviewed in [95]) could serve as enzootic ZIKV vectors. Their ZIKV vector competence as well as the host competence of New World monkeys and other small mammals that have begun to be tested [96], should be evaluated experimentally. Importantly, establishment of a ZIKV sylvatic transmission cycle in the Americas would render future eradication efforts practically impossible, and also might inhibit our ability to control the ongoing outbreak of CZS.

V. Features of primary human infection

A. Benign illness in adults and children (Scott Weaver)

Evidence that Zika virus typically causes an inapparent or benign illness dates back to the the first carefully documented case of human ZIKV infection by Simpson in Uganda, possibly a laboratory infection [earlier reports from West Africa were actually infections with the closely related Spondweni virus [97]]. The illness included a slight headache on day one with no other signs or symptoms. On day 2 a “diffuse pink maculopapular rash, which covered the face, neck, trunk and upper arms” appeared, gradually spreading to involve all four limbs, the palms of the hands and the soles of the feet. A low-grade fever (99.4F) also appeared along with slight malaise and back pain. By day 3, the patient returned to normal aside from a persistent rash on the trunk and limbs, disappearing by day 5.

During the first well-characterized (albeit mainly retrospectively) 2007 outbreak in Yap, many children and adults (an estimated 68-to 77% of persons 3 years of age or older were infected). Common signs and symptoms included rash, fever, arthralgia, and conjunctivitis, with myalgia, headache, retro- orbital pain, edema, and vomiting less common, but no severe manifestations, hospitalizations, or deaths associated with ZIKV infection [98]. Only 18% of persons infected were estimated to have had clinical illness (95% CI: 10-27%). As ZIKV has
spread to other parts of Oceania and to the Western Hemisphere, and as outbreaks have been detected in Asian locations such as Singapore, this typical clinical syndrome has remained, although estimated apparent:inapparent ratios have ranged slightly higher, probably due to increased awareness of the virus among patients and health care workers. However, rash, fever, arthralgia and conjunctivitis have remained common signs and symptoms in most outbreaks [99].

B. Persistent infection and sexual transmission (Geraldine O. Schott-Lerner, Shelton S. Bradrick and Mariano A. Garcia-Blanco)

1. Features of persistent infection

Dramatic findings during the past 2 years have demonstrated the persistence of ZIKV in several location following human infection. Several studies have investigated the presence and persistence of ZIKV in the male and female genitourinary (GU) tract by testing sperm, urine, and vaginal secretions from infected patients over extended periods of time. Remarkably, ZIKV RNA can persist at high levels in sperm months after resolution of symptoms [100-103]. In female patients, vRNA was detected in vaginal secretions for up to ~2 weeks after the onset of symptoms [24, 104]. The sexual transmissibility of ZIKV and its persistence in reproductive tract tissues and secretions are features that were not commonly observed in other flaviviral infections in humans.

Animal studies have recapitulated some of these clinical observations concerning GU persistence and tropism of ZIKV (Table 2). Two studies examined the effects of ZIKV infection on murine male reproductive tissues and demonstrated persistence of virus in testis and epididymis as well as histopathologic tissue lesions and inflammation [105, 106]. Although the translation to humans of these studies is unclear, they nonetheless raise the question of long-term consequences of ZIKV in the human male reproductive system. Studies in pregnant wild-type (WT) female mice showed that vaginal exposure to ZIKV results in local infection, growth restriction, and brain infection of developing fetuses [107]. Intraperitoneally or intravenously inoculated WT mice normally do not develop viremia, so these results highlight a strong tropism of ZIKV for the GU tract. A third study showed persistent shedding of ZIKV RNA in semen from infected immunodeficient male mice and sexual transmission to uninfected females [108]. One study in rhesus and cynomolgus macaques showed that ZIKV persisted in seminal fluids and male and female reproductive tissues, and another indicated longer persistence of vRNA in maternal blood of infected pregnant rhesus macaques [22, 109].

2. Evidence of sexual and other forms of non-mosquito-borne transmission

Foy et al. described the case of two patients returning from Senegal in 2008 that were diagnosed with Zika after serological testing. Although their clinical signs and symptoms were consistent with flavivirus infection, one developed prostatitis and hematospermia. His wife subsequently developed a febrile illness and serological tests (viral neutralization assays) were consistent with ZIKV infection. It was established that she had never been to Asia or Africa nor had travelled outside the U.S. in over a year, suggesting that the virus was sexually transmitted [23]. In 2016, several reports confirmed sexual transmission of ZIKV from males to females and both male-to-male, and female-to-male transmission has also been documented, albeit less frequently [110-114].

Other than sexual transmission, the most likely non-mosquito transmission route is via contaminated blood products [115] and this route has been documented since the inception of the ZIKV epidemic in the Americas [116-118]. Two studies looking at the presence of ZIKV RNA in donated blood in the US concluded that few samples tested positive (1 in 93,000 and 1 in ~25,000) and screening of donors’ travel history should prevent contaminated blood and infection of recipients; hence blood transfusion is not believed to be a major mode of transmission in the US [119, 120]. Specific guidelines to handle blood products are being
reviewed and updated [121, 122]. Upcoming discussions as to how to screen blood donations are a matter of urgent importance, while novel techniques of high-throughput screening are under development [123].

3. Models of sexual transmission

Animal models have been valuable to study mechanisms of both sexual and vertical transmission of ZIKV, including both mice (see VI.D.2) and nonhuman primates (see VI.D.3). Although it is clear that ZIKV tropism is critical to its transmission and biology, few published studies have examined mechanisms of GU tract infection and more research is needed to understand why this virus is so successful in those tissues compared to other closely related flaviviruses. Furthermore, the connections between sexual transmission and vertical transmission (i.e. can the sexual route of infection increase the chance of fetal infection?) remain unexplored.

VI. Mechanisms and consequences of maternal-fetal transmission

A. Spectrum of congenital defects (Caroline Marrs, George Saade)

ZIKV infection during pregnancy can cause both pregnancy loss and congenital malformations, including microcephaly and a range of other central nervous system and ocular malformations [124](Table 3). Counseling pregnant and reproductive-aged women has been difficult due to complex diagnostic algorithms and evolving data on the risk of both sexual and vertical transmission [112].

The screening approach in pregnancy is based on patient history of potential exposure to ZIKV through residence, travel or sexual contact, maternal ZIKV antibody testing and/or detection of viral RNA with PCR testing of maternal blood and urine, prenatal fetal ultrasound, as well as amniocentesis in some cases. Diagnosis can be difficult due to antibody cross-reactivity between ZIKV and other flaviviruses, the limited window of time that antibodies and/or viral particles persist in the bloodstream, and the asymptomatic nature of most ZIKV infections. Laboratory testing and prenatal ultrasound screening algorithms have been published by the CDC and updated with the evolving scientific knowledge [125, 126].

It is important to note that there is prolonged persistence of viral RNA in human blood and urine in pregnancy. ZIKV RNA has been detected in the serum of non-pregnant persons up to 11-13 days after symptom onset, while ZIKV RNA has been detected in serum of pregnant women up to 10 weeks after symptom onset [127-129]. However, the presence of RNA does not indicate infectious Zika virus, and therefore there is still confusion about how long a woman and her fetus are at risk of maternal-fetal transmission. There is very limited data about the risk of maternal-child transmission via breastmilk. Case reports and small case series have not found evidence of transmission in spite of presence of viral particles and even infective particles in breastmilk [130, 131]. The long-term effect of neonatal infection is unknown. Given the numerous benefits of breastfeeding, the WHO and the CDC have recommended that infants born to mothers with suspected or confirmed ZIKV infection, or who are at risk of exposure, should be fed according to normal infant feeding guidelines [132, 133].

There is substantial evidence for a causal relationship between maternal ZIKV infection and fetal/neonatal microcephaly and other brain insults [124]. Table 3 lists the other birth defects that have been reported in pregnant women with suspected or confirmed ZIKV infection. Most defects are of the central nervous system, and there is evidence that ZIKV has a predilection for neural cells [134-137]. Microcephaly is not typically apparent until the late second or early third trimester, when a woman is often past the legal window for termination of pregnancy should she desire it.

Since the initial outbreak in Brazil, there has been an effort to standardize the prenatal definition of microcephaly, which previously had not been defined consistently in the literature. This issue is further compounded by the limitation in fetal measurements: fetal head size can
only be estimated prenatally, and this estimate has a wide overlap between normal and abnormal. The Society for Maternal Fetal Medicine (SMFM) published a statement regarding ultrasound diagnosis of microcephaly in the setting of the Zika outbreak [138]. In summary, the Society recommended defining isolated microcephaly as a fetal head circumference of ≥ 3 standard deviations below the mean for gestational age, while pathologic microcephaly is considered certain when the fetal head circumference is smaller than 5 standard deviations below the mean for gestational age. This is similar to the WHO’s recommendations [139].

Because the measurements are related to average fetal dimensions for gestational age, it is crucial to ensure accurate pregnancy dating and to use an appropriate reference growth curve. In the United States, a recent large multicenter cohort study reported nomograms for various fetal biometry measurements, including HC (the NICHD National Fetal Growth Study), stratified by race/ethnicity [140]. The drawback in this setting is that it does not report cutoffs lower than the third percentile (which is roughly equivalent to the 2nd SD). The International Fetal and Newborn Growth Consortium (INTERGROWTH-21st) collected data on large populations of healthy pregnant women across the globe to describe normal fetal growth and has published the nomograms [141]. Using these more modern growth references should help better identify truly pathologic microcephaly.

In addition to CNS malformations, there is evidence that ZIKV infection can lead to early pregnancy loss and later fetal demise [142-144]. While the primary concern has been microcephaly, some have raised the concern for long-term, more subtle effects of prenatal infection [5].

The Centers for Disease Control and Prevention (CDC), in collaboration with local and state health departments, established the U.S. Zika Pregnancy Registry to monitor outcomes of pregnant women with laboratory evidence of possible ZIKV infection and their infants [145]. ZIKV-associated birth defects were reported in 5% of infants with laboratory evidence of possible ZIKV infection, and in 10% of infants with confirmed infection. The rate was 15% in women with confirmed infection in the first trimester, suggesting early infection leads to worse outcomes. Brazil and other South American countries are likewise collecting registries in an attempt to better characterize incidence, risk of transmission, and outcomes. As new data emerge, national and international guidance for testing, surveillance, and management of maternal ZIKV infection will evolve.

A. Epidemiology of congenital Zika syndrome (Guilherme Ribeiro, Uriel Kitron)

Between July and September of 2015, physicians in Northeastern Brazil performing prenatal ultrasound began to notice an increase in the frequency of fetuses with congenital brain abnormalities. In October, 2015, following the continued rise in the number of fetuses and newborns presenting with microcephaly, particularly in the State of Pernambuco, the Brazilian Health Ministry issued a declaration of a national public health emergency, which was followed by a global declaration by the WHO in February, 2016. At that time, there was no direct scientific evidence of a causal relationship between ZIKV infection during pregnancy and congenital brain defects in fetuses or newborns, but such an association was highly suspected because epidemics of ZIKV infection preceded the rise in congenital malformations in northeastern Brazil. In addition, one month after the Brazilian public health emergency declaration, researchers from French Polynesia, where a large outbreak of ZIKV infection occurred between October 2013 and March 2014, also reported an unusual increase in the number of fetuses and newborns with brain abnormalities approximately one year following the beginning of the ZIKV outbreak [146].

Evidence for a causal association between ZIKV and congenital abnormalities has accumulated based on clinical, epidemiological, and experimental studies. Several case reports have shown the presence of ZIKV, viral RNA (vRNA), and/or IgM antibodies against ZIKV in blood, amniotic fluid and other tissues of newborns and stillbirths presenting with congenital
brain defects [5, 7, 144]. In addition, strong spatial and temporal correlations between ZIKV epidemics and Guillain-Barré syndrome (GBS) in adults, as well as microcephaly in newborns, were observed in Salvador, Brazil [3]. There, a lag time of 30–33 weeks between peaks in the number of exanthematous cases suspected of ZIKV infection and the number of suspected cases of microcephaly was demonstrated, suggesting a greater risk of congenital malformations when women are infected by ZIKV during the first trimester of pregnancy. A population-level study performed on French Polynesian data also showed that ZIKV infections during the first trimester of pregnancy were associated with a higher risk of microcephaly [147].

Definitive epidemiological evidence of a link between ZIKV infection during pregnancy and CZS was derived from two studies. In a cohort of pregnant women undergoing fetal ultrasonography in Rio de Janeiro, congenital abnormalities were detected in 12 (29%) of fetuses of 42 ZIKV-positive women, but in none of 16 ZIKV-negative women [148]. Another study conducted in Recife enrolled 32 microcephaly cases, as well as 64 control neonates without microcephaly, and found that 13 (41%) of the cases and none of the controls had laboratory evidence for ZIKV infection (OR 55.5; 95% CI: 8.6–∞) [149]. Overall, analysis of data from several sites indicated that the risk of microcephaly is mainly in the first trimester of pregnancy [150]. In vitro and experimental animal studies also support the ability of ZIKV to cause abnormalities during brain development, and models for CZS are detailed below (Section 3.2). The evidence for causality of ZIKV infection and birth defects has been extensively reviewed by Rasmussen et al. [124] and Krauer et al. [151].

Since the first cases of microcephaly were detected in northeastern Brazil, 24 countries and territories in the Americas have reported CZS and by March 10, 2017 the Pan American Health Organization (PAHO) recorded 2,767 confirmed cases associated with ZIKV infection [152]. Brazil accounts for the vast majority of congenital disease with 2,386 (86%) of all confirmed cases, followed by Colombia (128 cases). The USA has reported 52 cases of CZS [152], although actual numbers are likely greater given the difficulty in performing laboratory confirmation of ZIKV infection by serology during pregnancy, and in newborns suspected of congenital malformations (see section 3.1.1).

While microcephaly has been the most obvious congenital complication associated with ZIKV, there is growing evidence for additional manifestations that may not be as pronounced at birth or that may only manifest later in infancy. However, during the initial months after recognition of this emerging congenital disorder, identification and reporting of CZS cases were based mainly on head circumference measurements, targeting only microcephaly. Now that it is clear that a small head size (based on sex and gestational age) at birth may not accompany all cases of CZS, pediatricians should be aware of potential congenital deficits among infants and children presenting with delayed neuromotor and cognitive development, as well as visual and hearing impairments.

Several epidemiological questions regarding CZS remain unanswered, and research priorities need to be revisited. Ongoing cohort studies of ZIKV-infected pregnant women and their fetuses and newborns will help define and quantify the risks for vertical transmission, miscarriage, abortion, and CZS among newborns. In addition, these studies may help to identify modulating factors that increase or reduce the risk of congenital defects [i.e. the route of ZIKV acquisition by the mother – mosquito-borne vs. sexual - and the preexistence of antibodies against other flaviviruses following natural infections, such as dengue virus (DENV), or via immunization, e.g., yellow fever (YF) vaccination]. The follow-up of children with CZS will also help elucidate the types and degrees of cognitive, motor, visual, hearing, and other neurological impairments, as well as survival rates.

Finally, until all pregnant women are provided with accurate laboratory diagnosis to detect both symptomatic and asymptomatic ZIKV infections, novel screening criteria that can reliably identify in utero and peripartum congenital Zika cases must be developed and evaluated. Such criteria may have to incorporate the history of an illness clinically compatible with ZIKV.
infection during pregnancy, and results from periodic ultrasonography performed during gestation, in addition to the head circumference measures already in use.

B. Pathologic manifestations (Diane E. Griffin)

Pathologic changes associated with ZIKV infection have been evaluated both in clinical specimens from humans and in tissues from experimentally infected immunocompetent mice and non-human primates (NHP). Organs susceptible to infection that have received the most attention are the placenta, brains and eyes after congenital infection.

**Placenta** – In humans, histologic examination of placentas from women with a history of ZIKV infection showed viral antigen in Hofbauer cells and histiocytes accompanied by villous inflammation, edema, trophoblastic epithelial lesions and calcifications [153]. Placentas from infants carried to term were small and showed chronic villitis, chorionitis, deciduitis and stromal fibrosis [154]. In monkeys, ZIKV was most abundant in the chorionic villous tissue [155]. In immunocompetent mice infected by intra-uterine inoculation there is infection of trophoblasts and endothelial cells accompanied by a loss of definition between placental layers, reduction of the labyrinth and hemorrhage suggesting compromise of the trophoblast-endothelial layer [156].

**Brain and spinal cord** – In the few infected human fetuses that have been examined pathologically, gross abnormalities include microcephaly with cortical thinning, agyria, hydrocephalus and calcifications in the cortex and subcortical white matter [7, 157]. Histopathology showed mononuclear inflammation, microglial nodules and hyperplasia, astrogliosis and neuronophagia in the affected regions [7, 153]. Similar macroscopic and microscopic abnormalities, along with abrupt slowing of white matter expansion, were observed in the brain of the fetus of a pigtail macaque infected subcutaneously at the equivalent of 28 weeks gestation [155].

Neuropathologic examination of infants carried to term that were stillborn or died shortly after birth has shown frequent presence of arthrogryposis, microphthalmia and small brains with multiple abnormalities including thickened leptomeninges, agyria, ventriculomegaly, parenchymal thinning and calcifications. Histopathology of these cases showed abnormal neuronal migration with polymicrogyria, meningeal glioneuronal heterotopia, and motor neuron loss and cerebellar cortical dysplasia. Viral antigen was most often detected in the meninges and inflammation was not prominent [154]. Pups born to Swiss Jim Lambert (SJL), but not C57BL/6, mice intravenously infected with large amounts (4x10^10-10^12 pfu) of ZIKV at 10-13 days gestation displayed intrauterine growth restriction and abnormal brains with cortical thinning and evidence of neuronal cell death [158]. After intrauterine infection, placentally transferred ZIKV infects endothelial cells, microglial cells and neural progenitor cells with evidence of microglial cell activation and cortical thinning [156]. Direct intracerebral infection of embryonic day 13.5 mice leads to infection of neural progenitor cells in the subventricular zone, decreased proliferation of radial glial cells and cortical thinning [159, 160]. Intracerebral infection of 1 or 3-week-old C57BL/6 mice leads to widespread infection and microglial cell (Iba1+) and astrocyte (GFAP+) activation. Apoptotic neuronal cell death was more abundant in younger animals. Particularly vulnerable neuronal populations were in the hippocampus, layers II and V of the cerebral cortex and cortical spinal tract [161].

**Eye** – Eye lesions in congenitally infected infants with and without microcephaly include malformation, optic neuritis and atrophy, chorioretinal scarring and atrophy, macular pigment stippling and lens subluxation [162-164]. Ocular malformations are also observed in congenitally infected mice [158], and in human adults after infection [165].

D. Laboratory models

1. **In vitro studies** (Marc Lecuit)

As with many other flaviviruses, ZIKV can replicate in a wide variety of human and non-human cultured cells [166]. Yet, ZIKV infection of humans displays unique clinical features
among flaviviruses [167]. They correlate with its specific in vivo tissue and cell tropisms, which are still being characterized and deciphered. Cardinal features of ZIKV, of critical clinical importance are that (i) it is transmitted by a mosquito bite but can also be transmitted sexually, (ii) it is able to actively cross the placental barrier and replicate in the placenta, and (iii) it can disseminate to the fetus and its developing brain, where it leads to severe neurodevelopmental defects, in particular in the developing cortex, resulting in microcephaly. Studies of cell and tissue samples from infected humans, as well as experimentally infected NHP and mouse lines, have shown that ZIKV infects a wide variety of tissues and cells, including the skin (human dermal fibroblasts, epidermal keratinocytes, and immature dendritic cells) [168], the testis (Leydig cells, sertoli cells, spermatogonia) [105, 106], vaginal epithelium and uterine fibroblasts [107, 169], placenta (trophoblasts, endothelial cells, Hofbauer cells) [153, 170-172], and the brain (cortical progenitors, mature neurons and astrocytes) [173-178]. It may also infect the eye (Ganglion cells, bipolar neurons, the optic nerve, cornea) and be found in body fluids including tears, saliva, semen, cervical mucus and urine [179-181].

In vivo and in vitro studies have shown that ZIKV cell tropism may reflect the expression pattern of virus co-receptors, such as AXL, a member of TAM receptor family, either directly, or as a signaling molecule that may modulate the type I-interferon receptor (IFNAR) pathway [168, 182-186]. TIM1 has also been reported to act as a co-receptor [168, 185]. Yet, because neither of these putative receptors is required for productive ZIKV infection, their significance with regard to ZIKV cell and tissue tropism remains to be fully determined [187]. As one would expect for an RNA virus, type I and III interferon and interferon-stimulated genes are also key restriction factors that modulate cell permissiveness to ZIKV [53, 188].

The blood phase of ZIKV infection has not been studied in detail so far, and it remains to be determined if ZIKV infects in vivo polymorphonuclear cells, lymphocytes and/or monocytes, and whether this may have an impact on ZIKV’s ability to cross the placental and blood-brain barriers.

**Crossing of the placental barrier**: whereas it has been established that ZIKV’s ability to cross the placental barrier is a key property that leads to CZS, the precise mechanism of crossing of the placental barrier remains only partially understood. Ongoing cohort studies will determine precisely the impact of pregnancy term on transmission efficiency. Studies with in vitro cultured cells and human placental explants have shown that mature syncytiotrophoblasts are not permissive to ZIKV, in contrast to extravillous cytotrophoblasts (EVT) [185, 189]. Yet, how ZIKV reaches EVT and whether EVT infection is the only factor that determines the ability to traverse the placental barrier remains to be determined. The non-permissiveness of syncytiotrophoblasts to ZIKV reflects, at least in part, its capacity to produce type III IFN, in contrast to EVT [188]. Although ZIKV has not been shown to replicate in syncytiotrophoblasts, it may transcytose these cells, although no experimental data have yet been published to support this hypothesis. Once in the placental tissue, ZIKV replicates in Hofbauer cells, the resident macrophages of the placenta; this has been observed in clinical samples of human placentas, in human placental explants infected experimentally, and in cultured Hofbauer cells. ZIKV replication in Hofbauer cells [171, 172, 185], as well as infection of endothelial cells of placental villus capillaries may constitute key amplification steps and lead to prolonged viral release in the fetal circulation, from where ZIKV can disseminate to the brain [153, 156, 185, 186].

**Infection of the fetal brain and neuropathology**: Most if not all viruses associated with fetal systemic infection also invade the brain. The precise mechanism by which ZIKV infects the brain remains unknown. More recently, ZIKV has been shown to infect primary human fetal cells targeting the microglial, resident brain macrophages [190]. Thus, the developing fetal blood-brain barrier is not as tight as in adults, and systemic infection and associated innate immune responses may also compromise the blood-brain barrier. Whether ZIKV actively infects endothelial cells critical to the blood-brain barrier or whether it transcytoses these cells remains unknown. Once in the brain parenchyma, ZIKV infects cortical progenitors, mature neurons as
well as astrocytes [173-177, 191, 192]. In contrast to other flaviviruses such as West Nile and DENV-4, ZIKV is able to infect cortical progenitors, and this is likely a critical feature that accounts for ZIKV-associated microcephaly [178]. The basis for ZIKV tropism for cortical progenitors and the mechanism by which it induces microcephaly remains unknown. The high level of AXL expression in these cells has been proposed as a factor accounting for their permissiveness to ZIKV [182].

2. Rodent models (Shannan Rossi)

In December of 2015, the total knowledge of ZIKV animal models was found in a handful of manuscripts written decades earlier. The first attempt to create a small animal model to understand ZIKV infection and pathogenesis used outbred white mice, rabbits, and guinea pigs [37]. It was immediately clear that, without adaptation, ZIKV did not produce any discernible disease in white mice [134]. To overcome this limitation, genetically modified mice with type-I interferon response deficits were used. By March 2016, the first report of lethal neurologic disease in mice lacking either type-I (IFNAR1) or types-I and –II interferon receptors was published [193](Table 4). These initial findings were quickly corroborated and extended by other investigators [53, 194, 195]; reviewed in [196].

Once adult mouse models were established, it became critical to develop models that exhibited severe disease in developing fetuses and neonates to better understand CZS. Building on the success of the initial immunodeficient mouse models, females [either WT treated with anti-IFNAR1 antibody (Ab), or IFNAR1-deficient] were mated to immunocompetent males and infected with ZIKV during pregnancy. The resulting pups were either resorbed or showed an intrauterine growth-restricted (IUGR) phenotype, depending on the gestational age of the pups at the time of infection [197]. ZIKV was detected in the heads and bodies of pups as well as in the placenta [197, 198]. In another murine model, the SJL mouse, ZIKV also infects fetuses, leading to intrauterine growth restriction and microcephaly [158].

However, a limitation of these IFN-deficient murine models is the lack of a normal innate response, even though the pups in most cases are phenotypically WT. Therefore, immunocompetent (WT) pregnant mice have also been used, infected either intravaginally, intrauterinely, intravenously, or intraperitoneally, resulting in pups born with IUGR, brain and eye abnormalities, as well as viral loads in the brain, spleen and placenta [107, 156, 158, 159]. Direct intracerebral infection of embryonic ICR mouse brains results in cell-cycle arrest, apoptosis, and inhibition of neural stem cell differentiation [199]. Direct inoculation into the uterine wall on embryonic day 10 but not 14 leads to increased infection of placental and fetal tissues fetal death [156]. Intraperitoneal infection of pregnant C57BL/6 mice results in infection of radial glia cells in the dorsal ventricular zone of fetuses, the primary neural progenitors of the cortex, reducing this population and leading to a reduced cavity of lateral ventricles and decreased cortical surface area [159].

More recently, the mouse model has also allowed for the study of sexual ZIKV transmission, as seen in humans (Section 3.1.4). ZIKV replicates in the male mouse reproductive tract [105, 193, 200], is present in the seminal fluid and can be efficiently transmitted to naive female mice during intercourse [108]. Currently, the contribution of human sexual transmission to congenital ZIKV infection is poorly understood, but could result in an altered pathogenesis compared to mosquito-transmitted infection. Given that intravaginal infection of WT mice can result in a localized ZIKV infection in the uterus [107], these models may provide a critical to understanding potential differences.

Murine models are currently being fine-tuned to better mimic human infection. Nevertheless, these models already provide an important approach to screen therapeutics and vaccines that can reduce or block transmission to the fetus. However, caution must be used when interpreting the results because the anatomy and gestational timing in mice is very different than that of humans.
3. Nonhuman primate models (Matthew T. Aliota, Thaddeus G. Golos, Thomas C. Friedrich, David H. O’Connor and Jorge E. Osorio)

Zika virus (ZIKV) likely originated and still is maintained in a sylvatic transmission cycle between nonhuman primates (NHP) and arboviral mosquitoes in tropical Africa and possibly Asia, where ZIKV antibodies have been detected in several monkey species [41]; for a review see [43]. Indeed, ZIKV was first isolated from a sentinel rhesus macaque (Macaca mulatta) in 1947 in Uganda [37], but until recently, data regarding ZIKV pathogenesis in NHP were limited. This has prompted the development of NHP models that now serve as useful platforms to study ZIKV pathogenesis, candidate therapies, and vaccines. Macaque monkeys [e.g., rhesus, cynomolgus (Macaca fascicularis), and pigtail (Macaca nemestrina)] have been the species of choice for ZIKV NHP studies to date (Table 5). Macaques are widely used in both infectious disease and obstetric research because their close relationship with humans provides similarities in immunobiology, fetal development, and disease outcomes, among others.

Macaques also support ZIKV replication without viral adaptation. Because of the animals’ size, macaque studies allow longitudinal and invasive tissue and fluid sampling to understand the kinetics of virus replication and antiviral immunity in an immunocompetent host. Macaques thus provide a system for rigorous preclinical evaluations of interventions. This model also comes with some limitations including cost, reduced power because of small group sizes, and the limited number of centers with the expertise and size to conduct macaque studies.

Recent studies in macaques established that Asian/American-lineage ZIKV infection of NHPs recapitulates key features of human infection in both pregnant and non-pregnant animals [22, 109, 201], including mild weight loss, rash, and elevated liver enzymes at early times post-infection [202]. In some experiments, ZIKV infection also resulted in elevated body temperature for up to 10 days post-infection [203]. Viremia peaked 2 to 6 days after infection and typically became undetectable by day 10 in ZIKV-inoculated rhesus macaques [22, 109]. ZIKV RNA also has been detected in urine, saliva, and the cerebrospinal fluid of some animals after clearance from the blood [22, 202], and sporadically in seminal fluid and vaginal secretions [22, 109]. Although vRNA is typically cleared from blood within approximately 10 days, in some studies vRNA also was detected in tissues including secondary lymphoid organs, the male reproductive tract, the intestines, brain and spinal cord several weeks after acute infection [201-203]. Infected animals developed humoral and cell-mediated immune responses that protected against challenge with homologous and heterologous ZIKVs [32, 109], indicating that this model will be useful for preclinical evaluation of vaccine candidates as well as the protective efficacy of passive immunization against ZIKV [204, 205].

The structure of the placenta and the organization of the maternal-fetal interface is remarkably diverse among mammals [206]. The hemochorial villous structure of the macaque placenta, and the villous and extravillous pathways of trophoblast differentiation represent the closest available experimental model to human placentation [207-209]. In particular, extravillous placental trophoblasts migrating from the placenta to remodel endometrial spiral arteries are noted in both macaque and human pregnancy [209, 210]. Extravillous trophoblasts have been proposed as a target of ZIKV and a conduit of ZIKV access to the fetal compartment [185]. There are unique populations of immune cells in the decidua [211] and within the placenta itself, including placental macrophages (Hofbauer cells) [212]. Both cell populations are permissive for ZIKV infection [172, 176, 190, 213], which reinforce the strength and relevance of the NHP model. The long gestation period (165-180 days) of macaques also provides a realistic model for human fetal development. Thus, macaques provide a close representation of the human morphological, developmental, and immune environment at the maternal-fetal interface, giving them a unique role in modeling the impact of pathogens on pregnancy and both fetal and maternal well-being.
In pregnant rhesus macaques, ZIKV viremia can persist for at least 71 days [22], and is associated with decreased fetal head growth velocity and consistent vertical transmission [214]. Strikingly, significant ocular pathology was noted in fetuses of dams infected during the first trimester [214]. Persistent viremia and retinal and optic nerve pathology and visual dysfunction have been noted in pregnant women [128, 129, 215] and neonates [216], respectively. Similarly, infection of a single pregnant pigtail macaque resulted in in utero transmission with reduced growth of the fetal brain, white matter deficiency and gliosis, and axonal damage [155]. ZIKV RNA was detected in the chorionic villous tissue of the placenta as well as the fetal brain and liver, suggesting trans-placental transmission followed by ZIKV invasion and injury to the fetal brain. Although the dam showed no clinical signs of infection, ZIKV RNA was detected in the maternal brain, eyes, spleen, and liver [155]. These studies indicate that macaques can serve as a powerful model to investigate ZIKV pathogenesis in the developing fetus and can be used to elucidate the subtleties of CZS, in which microcephaly is the most severe of a range of possible sequelae.

Both field- and laboratory-based studies in other NHP species, particularly in New World monkeys, should be a research priority; the conditions exist for ZIKV to establish an enzootic monkey-mosquito cycle in the Americas, as occurred for YF virus (YFV) hundreds of years ago following its importation from Africa during the slave trade. The public health implications of sylvatic ZIKV would be complex, but establishment of an enzootic cycle would make elimination from the Americas next to impossible, and might increase human exposure in rural areas. Such studies will be vital for understanding potential reservoir hosts and the transmission dynamics in the Americas.

VII. Current status of vaccine development (Pei-Yong Shi)

In response to the recent ZIKV epidemics, vaccine candidates have been developed at an unprecedented pace. Four distinct approaches have been taken: subunit vaccines, inactivated vaccines, chimeric flavivirus vaccines, and live-attenuated vaccines. Among these candidates, subunit and inactivated vaccines have shown efficacy in both mice and NHPs, and several of these candidates have already advanced to phase 1 clinical evaluation in humans [217]. Chimeric virus and live-attenuated vaccines have shown murine efficacy [218, 219], but their efficacies in NHPs remains to be reported. These promising preclinical results are not surprising because similar approaches have been successful for development for other flavivirus vaccines. Clinically approved vaccines are currently available for four flaviviruses, including (i) a live-attenuated vaccine for YFV (YFV 17D); (ii) an inactivated vaccine for Tick-borne encephalitis virus; (iii) inactivated and live-attenuated (JEV SA 14-14-2) vaccines for Japanese encephalitis; chimeric flavivirus (YFV 17D backbone expressing JEV prM-E genes) vaccines for JEV; and (iv) chimeric flavivirus (YFV 17D backbone expressing DENV1-4 prM-E genes) vaccines for DENV [220].

(i) Subunit vaccines have been developed expressing ZIKV prM-E or M-E proteins using one of the three vectors, including plasmid DNA [205, 221], modified mRNA [222, 223], or adenovirus serotype 52 [204]. For the modified mRNA approach, RNA was in vitro transcribed using 1-methylpseudouridine (instead of natural uridine to minimize the indiscriminate activation of innate immunity) and encapsulated within lipid nanoparticles for in vivo delivery. To minimize the potential adverse effect of cross-reactive Ab-mediated enhancement among ZIKV and other flaviviruses, the prM-E coding sequence was modified to eliminate the flavivirus-conserved fusion-loop epitope in the E protein; immunization of animals with this mRNA vaccine diminished the production of antibodies capable of enhancing DENV infection in cells and mice [223]. For the plasmid DNA approach, two doses were needed to protect NHPs from ZIKV challenge. In contrast, a single dose of mRNA or adenovirus serotype 52 vectored vaccine conferred protection, among which a high dose of 50 µg of the mRNA vaccine elicited sterilizing immunity.
(ii) A purified inactivated vaccine using ZIKV strain PBVABC59 required two doses to confer protection in NHPs [204]. This inactivated vaccine is currently under joint development by the Walter Reed Army Institute of Research and Sanofi Pasteur. To increase the manufacture yield of this vaccine, Yang et al. engineered the ZIKV PBVABC59 strain with three Vero cell-adaptive mutations that could increase titers by 25-300-fold when cultured on Vero cells, which are an approved vaccine substrate [224]. This technology has the potential to significantly reduce the cost of this promising vaccine.

(iii) A chimeric flavivirus vaccine uses available flavivirus vaccines backbones (e.g., YFV 17D or 3'UTR deletion DENV vaccine) to express ZIKV prM-E genes. To support the feasibility of this approach, Xie et al. recently reported a chimeric DENV-2 containing the ZIKV prM-E genes that fully protected against WT ZIKV challenge in the A129 mouse model; reciprocally, a chimeric ZIKV containing the DENV-2 prM-E genes completely protected WT DENV-2 challenge [218]. Along the same lines, Stephen Whitehead and colleagues are currently developing such chimeric vaccines using the 3'UTR deletion DENV vaccine backbones (personal communications). Together with the NIAID dengue vaccine currently in phase III clinical trial, the addition of the chimeric ZIKV vaccine may provide a dual dengue-and-Zika vaccine, which could be useful for populations living in regions endemic for both DENV and ZIKV.

(iv) A live-attenuated ZIKV vaccine has the advantages of single-dose immunization, a rapid and robust immune response, and potential long-lived protection. Using an infectious cDNA clone of Cambodian strain FSS13025 of ZIKV closely related to all American strains [225], Shan et al. engineered a live-attenuated vaccine candidate with a 10-nucleotide deletion in the 3'UTR. This vaccine candidate elicited a sterilizing immunity and robust T cell response in mice after immunization with a single dose of 10 infectious particles. Besides potent efficacy, this live-attenuated vaccine candidate also exhibited reduced neurovirulence and other indications of a high safety profile [219]. Although the correlation between protection against viremia and neutralizing Ab titers has been well established [205, 221], it is unknown whether sterilizing immunity and robust T cell response are required to avert transplacental transmission of ZIKV during pregnancy. Answering this question will be critical for the development of a vaccine to protect against CZS. Two other questions critical to Zika vaccine development are: (i) whether antibody enhancement between the closely related DENV and ZIKV flaviviruses might result in the potential for vaccination to influence disease related to the other, and; (ii) how to eliminate the potential risk of vaccine-triggered GBS.

VIII. Current status of antiviral therapeutics (Raymond F. Schinazi, Christina Gavegnano, Bryan Cox, and Leda Bassit)

The need for safe, potent Zika virus antiviral agents. Recent estimates suggest that over 1.5 million individuals were infected with ZIKV during the American continental outbreak of 2014-2015 (WHO, 2015). As described above, ZIKV infection can result in neurodegenerative disorders, GBS, fetal abnormalities, and fetal microcephaly following infection of pregnant women [10, 128, 176, 226-228]. There are currently >3,000 pregnant American women with laboratory signs of ZIKV infection (https://www.cdc.gov/zika/geo/pregwomen-uscases.html). To date, there are no FDA-approved drugs to treat ZIKV infection, and the spread of this virus and ongoing pandemic necessitates expeditious identification of novel antiviral agents.

Drug characteristics to treat or prevent ZIKV infection. Due to its distinct pathogenesis, ZIKV presents unique challenges in developing and identifying antiviral agents that are safe, potent, and specific to prevent and treat infection in pregnant women. An ideal antiviral drug will meet unique pharmacologic criteria as a preventative or treatment option (Fig. 2). First and foremost, the drug must be pregnancy category A/B, as these agents do not impair the growing fetus or compromise the maternal-fetal interface. The drug must potently inhibit ZIKV replication devoid of toxicity across all relevant and permissive cell types including fibroblast, epithelial,
dendritic, liver, neuronal, and placental Hofbauer and trophoblast cells [153, 168, 171, 172, 176]. An ideal drug would be orally bioavailable for maintenance dosing with an expansive distribution profile. In addition, one can envision a slow release, nanoformulated drug that could be administered once by injection to would release active antiviral agent over the gestation period. The agent should accumulate in vivo at concentrations sufficient to eliminate viral replication, thereby mitigating development of resistant virus mutants. The innate antiviral type I interferon-response should ideally remain intact during therapy since these paracrine and autocrine cascades, and subsequent cellular activation, impact viral transmission across the placenta to the unborn fetus [172, 188, 229-231]. At the time of publication, several promising candidates have been identified that meet some of these criteria (Fig. 3)[177, 232-237].

**Landscape of ZIKV inhibitors - repurposing efforts and limitations of identified agents.** Drug repurposing offers the opportunity to expedite drug discovery. Barrow et al, reported 24 FDA-approved agents that inhibit ZIKV in Huh-7 hepatocytes and immortalized human stem cells [237]. Some of these are pregnancy category B drugs, like daptomycin, mefloquine, and palonosetron, but these compounds suffer from limited anti-ZIKV activity and fail to inhibit the virus in critical cell types. Xu et al screened >6,000 compounds, including >2,000 FDA-approved agents, using caspase-3 activity followed by ZIKV protein expression and cell viability as a readout for antiviral potency [177]. The screen identified niclosamide (a pregnancy category B drug) as a weak ZIKV inhibitor and emricasan as a potent inhibitor. Emricasan is a phase 2 inhibitor of caspase 3 under investigation for fatty acid liver disease. Although promising, it is unclear if long-term, steady-state plasma concentrations efficiently eliminate ZIKV. Additionally, it is uncertain if a caspase-3 inhibitor with anti-inflammatory properties impacts development of the unborn fetus and ability to mount innate and adaptive immunity in vivo.

Novel ZIKV inhibitors that act as traditional direct-acting antiviral agents have also been reported. Nucleoside analogs, like sofosbuvir and 7-deaza-2'-C-methyladenosine (MK-608), potently inhibit ZIKV replication in cellular assays and are efficacious in animal models [236]. The recent crystal structure of ZIKV polymerase, the target of nucleoside antiviral agents, will have great impact for the discovery of novel antiviral agents [233]. Peptidomimetic agents like CN-716 inhibit the ZIKV protease in vitro, but only weakly inhibit viral replication due to poor cellular penetration (summarized in [238]). Due to potential safety concerns, these compounds may not translate as therapeutic options for pregnant women, but could apply to other infected individuals.

**Towards a ZIKV cure.** Drug repurposing and discovery efforts have generated promising leads that block ZIKV replication. Elucidating treatment options for ZIKV requires understanding pharmacology, drug activity across relevant cell types, adequate drug distribution, safety, and intact immunity. Information obtained to date provides an excellent foundation for informed drug discovery efforts that address each of these factors in vitro and ex vivo. The ultimate result holds the promise of safe, specific, and potent antiviral agents that prevent transmission as pre-

**IX. Current status of diagnostic testing (Diogo M. Magnani, Michael Ricciardi, Esper G. Kallas, David I. Watkins)**

While it is relatively straightforward to detect ZIKV nucleic acids during the acute phase in blood, urine, saliva, and semen, it has proven more difficult to design rapid and effective diagnostics for prior ZIKV exposure [239]. This is reflected by the U.S. Food and Drug Administration (FDA) website where Emergency Use Authorization (EUA) has been obtained for 11 RNA based assays and only two tests for IgM [240]. Additionally, the Euroimmun kit detects IgM and IgG antibodies against the NS1 protein of Zika and has been approved by the Brazilian equivalent of the FDA, Agência Nacional de Vigilância Sanitária (ANVISA)[241, 242]. In patients who have received a flaviviral vaccine (DENV, YFV, or JEV) and/or have been infected with any flaviviruses in the past, some of these IgM assays may be difficult to interpret due to the cross-reactivity [125, 241, 243-246]. Thus, a positive IgM test needs to be confirmed with a laborious
plaque reduction neutralization test (PRNT), which itself may not even have sufficient specificity for persons who have been infected with multiple flaviviruses. To replace the labor intensive PRNT assay, a reporter virus system was recently developed to allow high-throughput and rapid quantification of neutralizing antibody titers for ZIKV and DENV [247]. IgM antibodies persist for 2-12 weeks in serum, and sera from individuals previously infected for more than 12 weeks would also need attempted confirmation with a virus neutralization-based method [125]. Additionally, since it is thought that the majority of Zika infections are asymptomatic [43], RNA- and IgM-based assays are only used for symptomatic infections and may therefore underestimate the actual number of infected individuals.

Detection of prior Zika infection, especially in dengue endemic areas, is therefore exceedingly difficult after 12 weeks post-infection and there are no FDA Emergency Use Authorized tests for detection of Zika-specific IgG after the acute phase. Indeed, Eurimmun offers the only kit for detection of Zika-specific IgG. The high levels of Ab cross-reactivity among Flaviviruses pose a formidable challenge for specific infection diagnosis in the chronic phase. A multiplex microsphere immunoassay using DENV and ZIKV E, NS1, and NS5 proteins was shown to improve diagnostic accuracy [248]. More recently a nanotechnology platform has been developed to detect IgG avidity against the NS1 protein of the Zika virus and this has been submitted to the FDA for EUA [249].

A new assay for the detection of Zika-specific IgG responses during the chronic phase was recently developed. This assay appears to be specific even in DENV-exposed individuals. The Z-Quick Test (Fig. 4) has been validated in more than 280 individuals from several cohorts, including 107 blinded samples from dengue-endemic regions. This test can detect previous ZIKV exposure at two weeks or later post onset of symptoms or three weeks or later after asymptomatic infection. A human IgG mAb P1F12 was isolated from a Zika-infected individual (who developed Guillain-Barré syndrome) in Brazil. Remarkably, despite being entirely germline-encoded, P1F12 exhibits high affinity and specificity for ZIKV and does not cross-react with any of the four DENV serotypes [250]. It appears that all ZIKV-infected individuals mount Ab responses against the epitope recognized by P1F12. This epitope is recognized by Abs in individuals previously infected by ZIKV, thereby preventing the binding of P1F12 to intact Zika virus. By contrast, Abs in the plasma from individuals previously infected by any of the DENV serotypes, do not prevent binding of P1F12. P1F12 may, therefore have potential as a diagnostic.

More tests to detect ZIKV-specific antibodies are urgently needed, as extensive epidemiological studies should be carried out in stored and previously collected cohort samples. More importantly, we need to provide tools for the decision-making process and counseling of pregnant women in areas at risk for ZIKV epidemics.

X. Current understanding of Zika emergence mechanisms (Scott C. Weaver, Andrew Haddow)

The reasons for the sudden and dramatic Zika epidemic in the Americas remain poorly understood. Undoubtedly increases in air travel with ever-increasing urbanization of the neotropics and reinfestation of rapidly expanding cities, combined with naïve populations provided ideal conditions for efficient ZIKV transmission and spread. Prolonged sexual transmission, unique among arboviruses, may also be contributing to transmission.

The epidemic in the Americas may also have been facilitated by changes in ZIKV virulence mediated by increased viremia or placental tropism, although there is no direct evidence for this; in fact, some African ZIKV strains are more virulent in murine models than strains from the Americas [193]. Urban vector-adaptive evolution is suggested by recent studies of an NS1 substitution that enhances Ae. aegypti infection [79], but other studies with ZIKV strains differing in this substitution have not identified comparable differences [52, 54]. Additional studies with wild mosquito populations are needed to further evaluate this NS1 change.
The competing hypothesis for phenotypic changes in ZIKV, which accompanied its introduction into the Americas, enhancing transmission or pathogenesis, is simply a stochastic introduction into a region primed for explosive transmission and spread. If cases of microcephaly linked to ZIKV infection reported in Thailand and Vietnam [251] are confirmed and are representative of Asian strain virulence, and endemic circulation maintains herd immunity sufficient to prevent major epidemics, no adaptive evolution would be needed to explain the 2015-2017 epidemic in the Americas. Better surveillance in Asia and Africa, facilitated by improved serodiagnoses, should eventually lead to answers to these questions.

XI. The future of the pandemic (Scott C. Weaver, Andrew Haddow)

The very limited information on the levels of circulation and geographic range of ZIKV in the Old World, and the lack of seroprevalence data from most of the Americas due to the serodiagnostic limitations described above, place major limitations on our ability to predict the future of the ongoing ZIKV epidemic and to assess current and future endemic transmission, including potential spillover from enzootic circulation as discussed above. A combination of spatial analyses and modeling indicated that over 1 million pregnant women and nearly 100 million persons living in the Americas could be infected during the current epidemic, suggesting tens of thousands of cases of CZS [252]. However, the trajectory of the American outbreak before herd immunity slows transmission, and the level of residual endemic exposure during the coming years is difficult to predict because basic parameters needed to accurately model transmission (e.g. minimum extrinsic incubation period in *Ae. aegypti*, length of infectious viremia in humans, typical vector longevity) are lacking. These include vector transmission efficiency (or the $R_0$ of typical infections) because the typical pattern of human infectious viremia remains poorly characterized (most studies only measure RNA genome copies and not infectious titers, and recently identified cell-associated ZIKV that persists in blood for many weeks may or may not be infectious for mosquito vectors) and the contribution of sexual and other forms of direct transmission are difficult to estimate as discussed above. Although transmission efficiency may differ based on viremia levels, vector competence and sexual transmission, the endemicity of the 4 DENV serotypes in the Americas for many decades suggests that ZIKV will continue to circulate in the human transmission cycle for the foreseeable future.

The recent arrival of CHIKV in the Americas, with epidemic circulation beginning about 18 months before that of ZIKV was detected, may provide additional clues regarding the future of ZIKV. Although exact comparisons of transmission efficiency are difficult due to limited data like those mentioned above, CHIKV and ZIKV are believed to have identical *Ae. aegypti*-borne human transmission cycles in the Americas. After its detection in the Caribbean in late 2013, epidemic CHIKV circulation peaked there the following summer, followed by a dramatic decline in reported cases in 2015. Combined with data on a 2015 reduction in imported cases in the U.S., which may serve as sentinels for levels of circulation in the Caribbean and Latin America, these results suggest that the ZIKV epidemic may typically peak regionally within one year. Although some regions of South America have not yet experienced major epidemics and thus may not yet have seen their peak of transmission, the ZIKV epidemic may be subsiding in some regions of the Americas.

Some models suggest that the cessation of American ZIKV epidemics could be followed by relatively low incidence of infection and disease for several decades [253]. However, the experience in India with CHIKV, where a major 2006-2007 epidemic after decades of absence was followed in 2016 by another wave of infections, suggests that herd immunity during the initial Indian CHIKV epidemic did not reach levels sufficient to inhibit transmission for these long time periods. Until levels of ZIKV herd immunity can be accurately measured serologically using improved assays less subject to flavivirus cross-reactions, it will remain difficult to predict future levels of endemic circulation.
The risk for a major ZIKV epidemic in Asia, even if American strains are found to be more transmissible or virulent for congenital infections, may be limited by long-term endemic exposure there, as discussed above. If endemic circulation in Asia and also probably Africa is maintained at levels that provide relatively stable herd immunity, outbreaks on the scale seen in completely naïve populations of the Americas may not be possible, and many women may become immune prior to pregnancy. Levels of CHIKV herd immunity measured in the Philippines, which are estimated to range from approximately 20-50% over time [254], suggest such a scenario for ZIKV. Although estimates of ZIKV infection incidence in Cambodia during 2007 were only about 1/8 those of DENV [255], this equates to about ½ that of each DENV serotype, still indicating extensive exposure considering the high levels of DENV hyperendemicity there. However, only with better surveillance facilitated by improved serodiagnostics will the data needed to understand ZIKV epidemiology and predict future trends become available.

XII. Concluding remarks (Scott Weaver).

The ZIKV epidemic in Oceania and the Americas and the discovery since 2013 of severe outcomes of infection including GBS and CZS have triggered remarkable advances in understanding the transmission, spread and adverse outcomes of infection. They have also driven unprecedented, rapid progress in animal model development, as well as in vaccine and therapeutic discovery with several Phase I clinical trials already completed. However, critical questions regarding the cause of the ongoing outbreak of CZS remain, especially:

1) Did the emergence occur due to changes pathogenicity or transmissibility in the ZIKV strain that spread into French Polynesia followed by the Americas, or did the outbreak occur following a stochastic series of introductions into naïve populations followed by air travel and mosquito-borne amplification?

2) Why were rates of CZS apparently higher in northeastern Brazil than in other regions of Latin American and the Caribbean?

3) Does immunity from prior flavivirus exposure affect ZIKV pathogenesis and the risk for fetal infection in pregnant women?

4) Will vaccines and therapeutics to prevent and control ZIKV infection become widely available considering the scientific, financial and logistic challenges?

5) Can ZIKV and other emerging, urban arboviruses such as DENV, CHIKV and YFV be controlled through improvements in traditional vector control programs, new approaches using genetically modified mosquitoes, Wolbachia bacteria, lethal trapping, combinations of these methods with vaccines?

Novel strategies are needed to contain ZIKV spread in the Americas and around the world. Better tools to understand virus spread, such as more reliable, inexpensive, and high-throughput serology assays, and the development of highly efficacious vaccines can enhance nearly all control methods under development. Hopefully, support for ZIKV research in all of these areas will be better sustained than in the past so that we will be better prepared to anticipate and respond to reemerging arboviruses such as CHIKV, DENV and YFV, as well as similar arboviruses yet to emerge.
Table 1. Members of the Global Virus Network Task Force on Zika Virus.

<table>
<thead>
<tr>
<th>Member</th>
<th>Institute</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Scott Weaver,</td>
<td>Institute for Human Infections and Immunity, University of Texas Medical</td>
</tr>
<tr>
<td>Chairman</td>
<td>Branch, Galveston, TX</td>
</tr>
<tr>
<td>2 Xavier Abad</td>
<td>IRTA-CReSA, Centre de Recerca en Sanitat Animal, Barcelona, Spain</td>
</tr>
<tr>
<td>Sazaly AbuBakar</td>
<td>University of Malaya, Kuala Lumpur, Malaysia</td>
</tr>
<tr>
<td>4 Nuria Busquets</td>
<td>IRTA-CReSA, Centre de Recerca en Sanitat Animal, Barcelona, Spain</td>
</tr>
<tr>
<td>Michael Diamond</td>
<td>Washington University School of Medicine, Seattle, WA</td>
</tr>
<tr>
<td>6 Susan J. Fisher</td>
<td>University of California, San Francisco, CA</td>
</tr>
<tr>
<td>7 Robert Gallo</td>
<td>Institute of Human Virology, University of Maryland School of Medicine,</td>
</tr>
<tr>
<td></td>
<td>Baltimore, MD</td>
</tr>
<tr>
<td>8 Antoine Gessain</td>
<td>Institut Pasteur, Laboratory Oncogenic Virus Epidemiology and Pathophysiology, Paris</td>
</tr>
<tr>
<td>9 Diane Griffin</td>
<td>Johns Hopkins Bloomberg School of Public Health, Baltimore, MD</td>
</tr>
<tr>
<td>10 Andrew Haddow</td>
<td>U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD</td>
</tr>
<tr>
<td>Giuseppe Ippolito</td>
<td>National Institute for Infectious Diseases, Rome, Italy</td>
</tr>
<tr>
<td>12 Esper G. Kallas</td>
<td>University of Sao Paulo, Brazil</td>
</tr>
<tr>
<td>13 Albert Ko</td>
<td>Yale University School of Public Health, CT</td>
</tr>
<tr>
<td>14 Alain Kohl</td>
<td>MRC-University of Glasgow, Centre for Virus Research, Scotland</td>
</tr>
<tr>
<td>15 Marc Lecuit</td>
<td>Institut Pasteur, Biology of Infection Unit, Paris, France</td>
</tr>
<tr>
<td>16 Julius Lutwama</td>
<td>Uganda Virus Research Institute, Entebbe, Uganda</td>
</tr>
<tr>
<td>John Mackenzie</td>
<td>Curtin University, Perth, Australia</td>
</tr>
<tr>
<td>18 Gene Morse</td>
<td>University at Buffalo, Buffalo, NY</td>
</tr>
<tr>
<td>19 Kenneth Olson</td>
<td>Colorado State University, Ft. Collins, CO</td>
</tr>
<tr>
<td>20 Jorge Osorio</td>
<td>University of Wisconsin and University of Antioquia Medical School, Medellin, Colombia</td>
</tr>
<tr>
<td>21 Janusz T. Paweska</td>
<td>National Institute for Communicable Diseases, Johannesburg, South Africa</td>
</tr>
<tr>
<td>22 Giovanni Rezza</td>
<td>Istituto Superiore di Sanità, Rome, Italy</td>
</tr>
<tr>
<td>23 Amadou Sall</td>
<td>Institut Pasteur de Dakar, Senegal</td>
</tr>
<tr>
<td>Raymond Schinazi</td>
<td>Emory University School of Medicine, Atlanta, GA</td>
</tr>
<tr>
<td>Cameron Simmons</td>
<td>University of Melbourne, Australia</td>
</tr>
<tr>
<td>26 Ed Tramont</td>
<td>National Institutes of Health, Bethesda, MD</td>
</tr>
<tr>
<td>Nikos Vasilakis</td>
<td>Institute for Human Infections and Immunity, University of Texas Medical</td>
</tr>
<tr>
<td>27 David Watkins</td>
<td>Branch, TX</td>
</tr>
<tr>
<td>Steve Whitehead</td>
<td>University of Miami, Miami, FL</td>
</tr>
<tr>
<td>29</td>
<td>National Institutes of Health, Bethesda, MD</td>
</tr>
</tbody>
</table>
Table 2. Animal models for ZIKV infection of the genitourinary tract and sexual transmission

<table>
<thead>
<tr>
<th>Reference, title</th>
<th>Model</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>[105] Zika virus infection damages the testes in mice.</td>
<td>WT male C57BL/6 mice treated with IFNα and IFNβ receptor 1-blocking monoclonal antibody</td>
<td>ZIKV persisted in testis and epididymis of male mice, preferentially infecting spermatogonia, primary spermatocytes and Sertoli cells. This was associated with tissue injury and seminiferous tubule destruction, and linked to lowered testosterone and oligospermia.</td>
</tr>
<tr>
<td>[106] Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice.</td>
<td>Ifnar1&lt;sup&gt;−/−&lt;/sup&gt; and WT C57BL/6 male mice</td>
<td>ZIKV induced inflammation in the testis and epididymis of male mice infected intraperitoneally and tissue damage persisting up to 60 days post-infection in mice.</td>
</tr>
<tr>
<td>[107] Vaginal Exposure to Zika Virus during Pregnancy Leads to Fetal Brain Infection.</td>
<td>Ifnar1&lt;sup&gt;−/−&lt;/sup&gt; and WT C57BL/6 female mice</td>
<td>Intravaginal exposure to ZIKV in WT pregnant C57BL/6 female mice led to persistence of viral RNA and infectious particles in the vagina and fetal growth restriction and brain infection.</td>
</tr>
<tr>
<td>[108] Frequent Zika Virus Sexual Transmission and Prolonged Viral RNA Shedding in an Immunodeficient Mouse Model.</td>
<td>Ifnar1&lt;sup&gt;−/−&lt;/sup&gt; mice</td>
<td>Infected male AG129 mice shed ZIKV in semen and infected female mice via sexual transmission; infectious virus was detected in semen from vasectomized and non-vasectomized males up to 58 days after infection, and 50% of females became infected post-mating. Fetal infection was detected in resulting pregnancies.</td>
</tr>
<tr>
<td>[109] Zika viral dynamics and shedding in rhesus and cynomolgus macaques.</td>
<td>Rhesus and cynomolgus macaques</td>
<td>Rhesus and cynomolgus macaques are susceptible to infection by ZIKV. Viral RNA was detected in saliva and seminal fluid 3 weeks after resolution of viremia in blood plasma.</td>
</tr>
<tr>
<td>[22] A rhesus macaque model of Asian-lineage Zika virus infection.</td>
<td>Rhesus macaques</td>
<td>Pregnant animals maintained persistent plasma viremia for more than 10 days post-infection, not the case for non-pregnant animals.</td>
</tr>
</tbody>
</table>
Table 3. Pregnancy and neonatal outcomes reported in mothers with ZIKV infection.

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early pregnancy loss</td>
<td>[142]</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>[143, 144, 148]</td>
</tr>
<tr>
<td>Microcephaly</td>
<td>[7, 145, 162, 163, 256]</td>
</tr>
<tr>
<td>Ocular abnormalities</td>
<td></td>
</tr>
<tr>
<td>Hearing loss</td>
<td>[145, 148]</td>
</tr>
<tr>
<td>Central nervous system lesions, including calcifications</td>
<td></td>
</tr>
<tr>
<td>Growth restriction</td>
<td>[148]</td>
</tr>
</tbody>
</table>
Table 4. Mouse models of Zika virus infection

<table>
<thead>
<tr>
<th>Reference</th>
<th>Mouse/age</th>
<th>Route*</th>
<th>Virus strain (dose)**</th>
<th>Pathologic findings</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Adult Mouse Models</strong></td>
</tr>
<tr>
<td>[193]</td>
<td>A129/的各种</td>
<td>IP, ID</td>
<td>FSS13025 (1x10^5 pfu)</td>
<td>A129 (age-dependent) and AG129 (age-independent) mortality, weight loss and viremia. High titers in organs like brain and testis.</td>
</tr>
<tr>
<td>[53]</td>
<td>各种KO strains/</td>
<td>SQ</td>
<td>H/PF/2013 (1x10^2-3 pfu)</td>
<td>Immunocompromised mice required for mortality, high titers in organs like brain, spinal cord and testis</td>
</tr>
<tr>
<td>[257]</td>
<td>A129/8-weeks</td>
<td>SQ</td>
<td>H/PF/2013 (various)</td>
<td>Muscle pathology observed</td>
</tr>
<tr>
<td>[179]</td>
<td>AG129/4-weeks</td>
<td>IP, SQ</td>
<td>H/PF/2013, Paraiba 2015</td>
<td>Establishes a model for evaluating treatments for ZIKV infections in the eye</td>
</tr>
<tr>
<td>[107]</td>
<td>C57BL/6 / 7-22 week</td>
<td>IVAG</td>
<td>FSS13025 (various)</td>
<td>Establishes vaginal tract as a highly susceptible site of ZIKV replication</td>
</tr>
<tr>
<td>[105]</td>
<td>C57BL/6 / 7 week</td>
<td>SQ</td>
<td>DakAr41519 H/PF/2013</td>
<td>Establishes consequences of ZIKV infection in the male reproductive tract of mice</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Fetal Mouse Models</strong></td>
</tr>
<tr>
<td>[197]</td>
<td>A129xwt wt treated α-IFN</td>
<td>SQ/1x10^3</td>
<td>H/PF/2013</td>
<td>E6.5</td>
</tr>
</tbody>
</table>

* Route: IP = Intraperitoneal, ID = Intradermal, SQ = Subcutaneous, IVAG = Intravaginal, H/PF = Horizontal/PF 
** Dose: pfu = plaque forming units

Note: The table provides a summary of mouse models used to study Zika virus infection, detailing the reference, mouse strain, route of administration, virus strain, and pathologic findings observed.
<table>
<thead>
<tr>
<th>Ref</th>
<th>Origin</th>
<th>Route</th>
<th>Age</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>[158]</td>
<td>C57Bl/6 SJL</td>
<td>IV/1x10^10</td>
<td>Brasil 2016</td>
<td>E10-13</td>
</tr>
<tr>
<td>[160]</td>
<td>ICR</td>
<td>IC/6.5x10^5</td>
<td>SZ01</td>
<td>E13.5</td>
</tr>
<tr>
<td>[159]</td>
<td>C57Bl/6</td>
<td>IC, IP/3x10^5</td>
<td>SZ01</td>
<td>E13.5</td>
</tr>
<tr>
<td>[198]</td>
<td>C57Bl/6 Ifnar1^-/-</td>
<td>SQ/1x10^3</td>
<td>H/PF/2013</td>
<td>E5.5 – 7.5</td>
</tr>
</tbody>
</table>

*IP – intraperitoneal; ID – intradermal; SQ – subcutaneous; IVAG – intravaginal; IV – intravenous

**pfu – plaque forming units
Table 5. Nonhuman primate models of ZIKV infection and disease

<table>
<thead>
<tr>
<th>Species</th>
<th>Virus inoculation route(s), strain(s)*</th>
<th>Pathology(ies) or fetal outcomes</th>
<th>Site(s) of virus detection</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rhesus macaque (<em>Macaca mulatta</em>)</td>
<td>$10^5$-$10^6$ PFU sc, ZIKV strain H/PF/2013, ZIKV strain MR766</td>
<td>No clinical signs</td>
<td>Plasma, saliva, urine, CSF, vaginal secretions</td>
<td>[22, 32]</td>
</tr>
<tr>
<td>Pigtail macaque (<em>Macaca nemestrina</em>)</td>
<td>$10^7$ PFU sc (given 5 times), ZIKV strain FSS13025</td>
<td>Fetal brain lesions, mild deciduitis in the dam</td>
<td>Fetal brain, eyes, testes; maternal eyes, kidneys, and chorionic villi of the placenta.</td>
<td>[155]</td>
</tr>
<tr>
<td>Cynomologus macaque (<em>Macaca fascicularis</em>), rhesus macaque</td>
<td>$10^5$ TCID$_{50}$ units sc, ZIKV strain PRVABC59; $10^6$ PFU sc Thai ZIKV isolate</td>
<td>No clinical signs</td>
<td>Plasma, urine, saliva, CSF, semen, vaginal secretions; lymphoid, neurologic, and reproductive tissues</td>
<td>[109]</td>
</tr>
<tr>
<td>Rhesus macaque</td>
<td>$10^5$ PFU IV, 2015 Brazilian ZIKV isolate</td>
<td>No clinical signs, no major histopathological changes</td>
<td>Plasma, whole blood, urine, saliva, CSF; lymphoid, cardiopulmonary, gastrointestinal, integument, and genitourinary tissues</td>
<td>[201]</td>
</tr>
<tr>
<td>Rhesus macaque</td>
<td>$10^4$-$10^6$ FFU sc (as 10 100 µl injections), ZIKV strain PRVABC59</td>
<td>Rash, fever, lymphadenopathy</td>
<td>Plasma, urine, Brain; lymphoid, neurologic, joint, and reproductive tissues</td>
<td>[202]</td>
</tr>
<tr>
<td>Rhesus macaque</td>
<td>$10^4$ PFU sc, ZIKV strain H/PF/2013</td>
<td>No clinical signs in the dam, prolonged viremia in the dam; decreased fetal head growth velocity, neutrophilic infiltration at the maternal-fetal interface and in fetal tissues, ocular pathology in the fetus</td>
<td>Maternal plasma, urine, saliva, spleen, lymph node, and decidua of the dam; amniotic fluid, fetal optic nerve, lymph node, pericardium, lung, placenta, bone marrow, liver, reproductive tract</td>
<td>[214]</td>
</tr>
<tr>
<td>Rhesus macaque</td>
<td>$10^3$-$10^6$ PFU sc, ZIKV strain PRVABC59, ZIKV strain</td>
<td>No clinical signs</td>
<td>Plasma, whole blood CSF; lymphoid and colorectal tissue</td>
<td>[258]</td>
</tr>
<tr>
<td>Macaque Type</td>
<td>ZIKV Strain</td>
<td>Dose</td>
<td>Clinical Signs</td>
<td>Organs/Secretions</td>
</tr>
<tr>
<td>-----------------</td>
<td>----------------------</td>
<td>-----------------------------</td>
<td>-------------------------</td>
<td>------------------------------------</td>
</tr>
<tr>
<td>Cynomologus</td>
<td>Brazil/ZKV/2015</td>
<td>$1 \times 10^4$ and $5 \times 10^5$ PFU sc, ZIKV strain PRVAC59, ZIKV strain FSS13025, ZIKV strain IBH30656</td>
<td>No clinical signs</td>
<td>Plasma, urine, saliva, and testes</td>
</tr>
<tr>
<td>Rhesus Macaque</td>
<td>ZIKV strain GZ01/2016</td>
<td>$10^5$ PFU sc, ZIKV strain GZ01/2016</td>
<td>Fever</td>
<td>Plasma, urine, saliva, lacrimal fluid, CSF; Brain, lymphoid, and digestive tract tissues</td>
</tr>
</tbody>
</table>

*PFU – plaque-forming units; sc – subcutaneous; TCID$_{50}$ – tissue culture infectious dose 50%
FIGURE LEGENDS

Fig. 1. Sylvatic and urban cycling of Zika virus and its mosquito vectors.

Fig. 2. Characteristics of ideal anti-Zika drugs (see text).

Fig. 3. Chemical structures of reported ZIKV inhibitors. A) FDA-approved drugs or B) Novel antiviral agents.

Fig. 4. Z-Quick Test overview [250]. Ninety-six-well ELISA plates are coated with an anti-flavivirus mAb overnight. The next day, plates are washed with PBS-T and block with 5% non-fat milk for 1 h at 37 °C. The plates are then washed, ZIKV is added to each well, and the plates are incubated at room temperature for 1 h. Plates are washed again, patient plasma is added to wells, and the plates are incubated for 1 h at 37 °C. The plates are then washed, the P1F12 ZIKV-specific antibody is added, and incubated for 1 h at 37 °C. During this step, if the patient was exposed to ZIKV, the antibodies in the patient’s plasma should block the binding of the P1F12 mAb. Next, the plates are washed, a HRP detection antibody is added, and the plates are incubated at 37 °C for 1 h. Lastly, the wells are washed, TMB is used to develop the HRP, and the wells are read using a spectrophotometer.
References


149. de Araujo TV, Rodrigues LC, de Alencar Ximenes RA, de Barros Miranda-Filho D, Montarroyos UR, de Melo AP, et al. Association between Zika virus infection and microcephaly


Acknowledgments

Work from the authors’ laboratories was funded by in part by United States National Institutes of Health grants: R01NS087539-S1 (to DEG), R21AI129607 (to RFS), and R24AI120942, R01AI121452 (to SCW) R01 AI107157-01A1 to TGG, R01AI116382-01A1S1 to DHO, and P51 OD011106 to the WNPRC.
**Fig. 1**

Sylvatic

- *Ae. africanus* (Africa)*
- *Ae. dalzieli* (Africa)
- *Ae. furcifer* (Africa)*
- *Ae. luteocephalus* (Africa)*
- *Ae. vittatus* (Africa)
- *Ae. apicoargenteus* (Africa)
- *Ae. hirsitus* (Africa)

Zone of emergence

- *Ae. metallicus* (Africa)
- *Ae. opok* (Africa)
- *Ae. taylori* (Africa)*
- *Ae. unilineatus* (Africa)
- *Ma. uniformis* (Africa)
- *An. coustani* (Africa)
- *Cx. perfuscus* (Africa)
- *Ae. vittatus* (Africa)

Urban

- *Ae. aegypti aegypti* (global)
- *Ae. albopictus* (global?)
- *Ae. polynensiensis* (Polynesia)
- *Ae. hensilii* (Polynesia)
- *Homo sapiens*

**Other Species**

- *Rhesus spp* (Africa)
- *Chlorocebus sabaeus* (Africa)
- *Cercopithecus spp* (Africa)
- *Colobus guereza* (Africa)
- *Erythrocebus patas* (Africa)
- *Pongo borneo* (SE Asia) ??
Fig. 2

<table>
<thead>
<tr>
<th>Ideal Anti-Zika Drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pregnancy category A/B</td>
</tr>
<tr>
<td>Potent ZIKV inhibition in relevant cell types</td>
</tr>
<tr>
<td>Oral bioavailability or long-acting antiviral</td>
</tr>
<tr>
<td>No drug-drug interactions</td>
</tr>
<tr>
<td>Peripheral distribution in key compartments including brain and placenta</td>
</tr>
</tbody>
</table>
Fig. 3

A

Emricasan
Mefloquine
Palonosetron
Niclosamide

B

Sofosbuvir
MK-608
NITD008
cn-716
Fig. 4

**ZIKV- Plasma will react and turn blue**
- ZIKV-specific P1F12 mAb w/ rhesus Fc
- anti-rhesus Fc mAb
- Human polyclonal Abs in plasma bind many sites
- Anti-flavivirus mAb

**ZIKV+ Plasma will not react or change color**
- P1F12 Binding Site
- Broad flavivirus epitope
- Anti-flavivirus mAb
- Human polyclonal Abs in plasma bind many sites
AVR_2017_269

Highlights Bray edits approved

- The Global Virus Network assembled a task force to respond to the outbreak of Zika virus infection in the New World.
- This report summarizes what has been learned about ZIKV disease in humans to date.
- Progress has been made in developing animal models, vaccines and therapeutics, with some Phase I trials completed.
- Critical questions remain regarding the cause of congenital abnormalities in infants of mothers infected with ZIKV.
- Novel strategies are needed to contain ZIKV spread in the Americas and around the world.